Advertisement

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Review ArticleAdult Brain
Open Access

Application of 7T MRS to High-Grade Gliomas

L. McCarthy, G. Verma, G. Hangel, A. Neal, B.A. Moffat, J.P. Stockmann, O.C. Andronesi, P. Balchandani and C.G. Hadjipanayis
American Journal of Neuroradiology October 2022, 43 (10) 1378-1395; DOI: https://doi.org/10.3174/ajnr.A7502

References

  1. 1.↵
    1. Server A,
    2. Josefsen R,
    3. Kulle B, et al
    . Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol 2010;51:316–25 doi:10.3109/02841850903482901 pmid:20092374
    CrossRefPubMed
  2. 2.↵
    1. Wilson TA,
    2. Karajannis MA,
    3. Harter DH
    . Glioblastoma multiforme: state of the art and future therapeutics. Surg Neurol Int 2014;5:64 doi:10.4103/2152-7806.132138 pmid:24991467
    CrossRefPubMed
  3. 3.↵
    1. Wolf KJ,
    2. Chen J,
    3. Coombes J, et al
    . Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. Nat Rev Mater 2019;4:651–68 doi:10.1038/s41578-019-0135-y pmid:32647587
    CrossRefPubMed
  4. 4.↵
    1. Hou LC,
    2. Veeravagu A,
    3. Hsu AR, et al
    . Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 2006;20:E5 doi:10.3171/foc.2006.20.4.2 pmid:16709036
    CrossRefPubMed
  5. 5.↵
    1. Zhu H,
    2. Barker PB
    . MRS and spectroscopic imaging of the brain. Methods Mol Biol 2011;711:203–26 doi:10.1007/978-1-61737-992-5_9] pmid:21279603
    CrossRefPubMed
  6. 6.↵
    1. Tkác I,
    2. Andersen P,
    3. Adriany G
    , et al. In vivo 1H NMRS of the human brain at 7 T. Magn Reson Med 2001;46:451–56 doi:10.1002/mrm.1213
    CrossRefPubMedWeb of Science
  7. 7.↵
    1. Horská A,
    2. Barker PB
    . Imaging of brain tumors: MRS and metabolic imaging. Neuroimaging Clin N Am 2010;20:293–310 doi:10.1016/j.nic.2010.04.003 pmid:20708548
    CrossRefPubMedWeb of Science
  8. 8.↵
    1. Dang L,
    2. White DW,
    3. Gross S, et al
    . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–44 doi:10.1038/nature08617 pmid:19935646
    CrossRefPubMedWeb of Science
  9. 9.↵
    1. Maudsley AA,
    2. Andronesi OC,
    3. Barker PB, et al
    . Advanced magnetic resonance spectroscopic neuroimaging: experts’ consensus recommendations. NMR Biomed 2021;34:e4309 doi:10.1002/nbm.4309 pmid:32350978
    CrossRefPubMed
  10. 10.↵
    1. Ricci R,
    2. Bacci A,
    3. Tugnoli V, et al
    . Metabolic findings on 3T 1H-MRS in peritumoral brain edema. AJNR Am J Neuroradiol 2007;28:1287–91 doi:10.3174/ajnr.A0564 pmid:17698529
    CrossRefPubMedWeb of Science
  11. 11.↵
    1. Bertolino N,
    2. Marchionni C,
    3. Ghielmetti F, et al
    . Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study. Phys Med 2014;30:702–07 doi:10.1016/j.ejmp.2014.03.002 pmid:24685182
    CrossRefPubMed
  12. 12.↵
    1. Cuccarini V,
    2. Antelmi L,
    3. Pollo B, et al
    . In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. Neurol Sci 2020;41:347–55 doi:10.1007/s10072-019-04087-9 pmid:31650436
    CrossRefPubMed
  13. 13.↵
    1. Kousi E,
    2. Tsougos I,
    3. Tsolaki E, et al
    . Spectroscopic evaluation of glioma grading at 3T: the combined role of short and long TE. ScientificWorldJournal 2012;2012:546171 doi:10.1100/2012/546171 pmid:22919334
    CrossRefPubMed
  14. 14.↵
    1. Laino ME,
    2. Young R,
    3. Beal K, et al
    . Magnetic resonance spectroscopic imaging in gliomas: clinical diagnosis and radiotherapy planning. BJR Open 2020;2:20190026 doi:10.1259/bjro.20190026 pmid:33178960
    CrossRefPubMed
  15. 15.↵
    1. Rutland JW,
    2. Delman BN,
    3. Gill CM, et al
    . Emerging use of ultra-high-field 7T MRI in the study of intracranial vascularity: state of the field and future directions. AJNR Am J Neuroradiol 2020;41:2–9 doi:10.3174/ajnr.A6344 pmid:31879330
    Abstract/FREE Full Text
  16. 16.↵
    1. Morrison MA,
    2. Lupo JM
    . 7-T magnetic resonance imaging in the management of brain tumors. Magn Reson Imaging Clin N Am 2021;29:83–102 doi:10.1016/j.mric.2020.09.007 pmid:33237018
    CrossRefPubMed
  17. 17.↵
    1. Lohmann P,
    2. Werner J-M,
    3. Shah N, et al
    . Combined amino acid positron emission tomography and advanced magnetic resonance imaging in glioma patients. Cancers (Basel) 2019;11:153 doi:10.3390/cancers11020153 pmid:30699942
    CrossRefPubMed
  18. 18.↵
    1. Hoff MN,
    2. McKinney A,
    3. Shellock FG, et al
    . Safety considerations of 7-T MRI in clinical practice. Radiology 2019;292:509–18 doi:10.1148/radiol.2019182742 pmid:31310177
    CrossRefPubMed
  19. 19.↵
    1. Otazo R,
    2. Mueller B,
    3. Ugurbil K, et al
    . Signal-to-noise ratio and spectral linewidth improvements between 1.5 and 7 Tesla in proton echo-planar spectroscopic imaging. Magn Reson Med 2006;56:1200–10 doi:10.1002/mrm.21067 pmid:17094090
    CrossRefPubMed
  20. 20.↵
    1. Barrett TF,
    2. Sarkiss CA,
    3. Dyvorne HA, et al
    . Application of ultrahigh field magnetic resonance imaging in the treatment of brain tumors: a meta-analysis. World Neurosurg 2016;86:450–65 doi:10.1016/j.wneu.2015.09.048 pmid:26409071
    CrossRefPubMed
  21. 21.↵
    1. Stephenson MC
    . Applications of multi-nuclear magnetic resonance spectroscopy at 7T. World J Radiol 2011;3:105–13 doi:10.4329/wjr.v3.i4.105 pmid:21532871
    CrossRefPubMed
  22. 22.↵
    1. Pradhan S,
    2. Bonekamp S,
    3. Gillen JS, et al
    . Comparison of single voxel brain MRS at 3T and 7T using 32-channel head coils. Magn Reson Imaging 2015;33:1013–18 doi:10.1016/j.mri.2015.06.003 pmid:26117693
    CrossRefPubMed
  23. 23.↵
    1. Mekle R,
    2. Mlynárik V,
    3. Gambarota G, et al
    . MRS of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 2009;61:1279–85 doi:10.1002/mrm.21961 pmid:19319893
    CrossRefPubMed
  24. 24.↵
    1. Younis S,
    2. Hougaard A,
    3. Christensen CE, et al
    . Feasibility of glutamate and GABA detection in pons and thalamus at 3T and 7T by proton magnetic resonance spectroscopy. Front Neurosci 2020;14:559314 doi:10.3389/fnins.2020.559314 pmid:33192247
    CrossRefPubMed
  25. 25.↵
    1. Li Y,
    2. Lafontaine M,
    3. Chang S, et al
    . Comparison between short and long echo time magnetic resonance spectroscopic imaging at 3T and 7T for evaluating brain metabolites in patients with glioma. ACS Chem Neurosci 2018;9:130–37 doi:10.1021/acschemneuro.7b00286 pmid:29035503
    CrossRefPubMed
  26. 26.↵
    1. Trattnig S,
    2. Springer E,
    3. Bogner W, et al
    . Key clinical benefits of neuroimaging at 7T. Neuroimage 2018;168:477–89 doi:10.1016/j.neuroimage.2016.11.031 pmid:27851995
    CrossRefPubMed
  27. 27.↵
    1. Emir UE,
    2. Larkin SJ,
    3. de Pennington N, et al
    . Noninvasive quantification of 2-hydroxyglutarate in human gliomas with IDH1 and IDH2 mutations. Cancer Res 2016;76:43–49 doi:10.1158/0008-5472.CAN-15-0934 pmid:26669865
    Abstract/FREE Full Text
  28. 28.↵
    1. Lupo JM,
    2. Li Y,
    3. Hess CP, et al
    . Advances in ultra-high field MRI for the clinical management of patients with brain tumors. Curr Opin Neurol 2011;24:605–15 doi:10.1097/WCO.0b013e32834cd495 pmid:22045220
    CrossRefPubMed
  29. 29.↵
    1. Wei RL,
    2. Wei XT
    . Advanced diagnosis of glioma by using emerging magnetic resonance sequences. Front Oncol 2021;11:694498 doi:10.3389/fonc.2021.694498 pmid:34422648
    CrossRefPubMed
  30. 30.↵
    1. Balchandani P,
    2. Naidich TP
    . Ultra-high-field MR neuroimaging. AJNR Am J Neuroradiol 2015;36:1204–15 doi:10.3174/ajnr.A4180 pmid:25523591
    Abstract/FREE Full Text
  31. 31.↵
    1. Li Y,
    2. Larson P,
    3. Chen AP, et al
    . Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 Tesla for characterization of differences in metabolite levels. J Magn Reson Imaging 2015;41:1332–41 doi:10.1002/jmri.24672 pmid:24935758
    CrossRefPubMed
  32. 32.↵
    1. Tkác I,
    2. Oz G,
    3. Adriany G, et al
    . In vivo 1H NMRS of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 2009;62:868–79 doi:10.1002/mrm.22086 pmid:19591201
    CrossRefPubMedWeb of Science
  33. 33.↵
    1. Berrington A, et al
    . A comparison of 2-hydroxyglutarate detection at 3 and 7 T with long-TE semi-LASER. NMR Biomed 2018;31 doi:10.1002/nbm.3886 pmid:29315915
    CrossRefPubMed
  34. 34.↵
    1. Verma G,
    2. Mohan S,
    3. Nasrallah MP, et al
    . Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla. J Transl Med 2016;14:274 doi:10.1186/s12967-016-1035-1 pmid:27659543
    CrossRefPubMed
  35. 35.↵
    1. Thomas MA,
    2. Hattori N,
    3. Umeda M, et al
    . Evaluation of two-dimensional L-COSY and JPRESS using a 3 T MRI scanner: from phantoms to human brain in vivo. NMR Biomed 2003;16:245–51 doi:10.1002/nbm.825 pmid:14648883
    CrossRefPubMedWeb of Science
  36. 36.↵
    1. Binesh N,
    2. Yue K,
    3. Fairbanks L, et al
    . Reproducibility of localized 2D correlated MR spectroscopy. Magn Reson Med 2002;48:942–48 doi:10.1002/mrm.10307 pmid:12465102
    CrossRefPubMed
  37. 37.↵
    1. Verma G,
    2. Hariharan H,
    3. Nagarajan R, et al
    . Implementation of two-dimensional L-COSY at 7 Tesla: an investigation of reproducibility in human brain. J Magn Reson Imaging 2014;40:1319–27 doi:10.1002/jmri.24510 pmid:24273136
    CrossRefPubMed
  38. 38.↵
    1. van Dijken BR,
    2. van Laar PJ,
    3. Holtman GA, et al
    . Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol 2017;27:4129–44 doi:10.1007/s00330-017-4789-9 pmid:28332014
    CrossRefPubMed
  39. 39.↵
    1. Kochalska K,
    2. Łazorczyk A,
    3. Pankowska A, et al
    . General technical remarks on (1)HMRS translational research in 7T. Pol J Radiol 2019;84:e190–97 doi:10.5114/pjr.2019.85147 pmid:31481990
    CrossRefPubMed
  40. 40.↵
    1. McKay J,
    2. Tkáč I
    . Quantitative in vivo neurochemical profiling in humans: where are we now? Int J Epidemiol 2016;45:1339–50 doi:10.1093/ije/dyw235 pmid:27794521
    CrossRefPubMed
  41. 41.↵
    1. Pan JW,
    2. Lo KM,
    3. Hetherington HP
    . Role of very high order and degree B0 shimming for spectroscopic imaging of the human brain at 7 Tesla. Magn Reson Med 2012;68:1007–17 doi:10.1002/mrm.24122 pmid:22213108
    CrossRefPubMed
  42. 42.↵
    1. Juchem C,
    2. Nixon TW,
    3. McIntyre S, et al
    . Dynamic multi-coil shimming of the human brain at 7 T. J Magn Reson 2011;212:280–88 doi:10.1016/j.jmr.2011.07.005 pmid:21824794
    CrossRefPubMed
  43. 43.↵
    1. Esmaeili M,
    2. Stockmann J,
    3. Strasser B, et al
    . An integrated RF-receive/B(0)-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7 T. Sci Rep 2020;10:15029 doi:10.1038/s41598-020-71623-5 pmid:32929121
    CrossRefPubMed
  44. 44.↵
    1. Andronesi OC,
    2. Arrillaga-Romany IC,
    3. Ly KI, et al
    . Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun 2018;9:1474 doi:10.1038/s41467-018-03905-6 pmid:29662077
    CrossRefPubMed
  45. 45.↵
    1. An Z,
    2. Tiwari V,
    3. Ganji SK, et al
    . Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: application for 2-hydroxyglutarate imaging in glioma patients. Magn Reson Med 2018;79:1851–61 doi:10.1002/mrm.26884 pmid:28833542
    CrossRefPubMed
  46. 46.↵
    1. Ganji SK,
    2. An Z,
    3. Tiwari V, et al
    . In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T. Magn Reson Med 2017;77:936–44 doi:10.1002/mrm.26190 pmid:26991680
    CrossRefPubMed
  47. 47.↵
    1. Shen X,
    2. Voets N,
    3. Larkin S, et al
    . A noninvasive comparison study between human gliomas with IDH1 and IDH2 mutations by MR spectroscopy. Metabolites 2019;9:35 doi:10.3390/metabo9020035 pmid:30791611
    CrossRefPubMed
  48. 48.↵
    1. Cohen AL,
    2. Holmen SL,
    3. Colman H
    . IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13:345 doi:10.1007/s11910-013-0345-4 pmid:23532369
    CrossRefPubMed
  49. 49.↵
    1. Sanson M,
    2. Marie Y,
    3. Paris S, et al
    . Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–54 doi:10.1200/JCO.2009.21.9832 pmid:19636000
    Abstract/FREE Full Text
  50. 50.↵
    1. Karpel-Massler G,
    2. Nguyen TT,
    3. Shang E, et al
    . Novel IDH1-targeted glioma therapies. CNS Drugs 2019;33:1155–66 doi:10.1007/s40263-019-00684-6 pmid:31768950
    CrossRefPubMed
  51. 51.↵
    1. Choi C,
    2. Ganji SK,
    3. DeBerardinis RJ, et al
    . 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624–29 doi:10.1038/nm.2682 pmid:22281806
    CrossRefPubMed
  52. 52.↵
    1. Choi C,
    2. Ganji S,
    3. Hulsey K, et al
    . A comparative study of short- and long-TE 1H MRS at 3T for in vivo detection of 2-hydroxyglutarate in brain tumors. NMR Biomed 2013;26:1242–50 doi:10.1002/nbm.2943 pmid:23592268
    CrossRefPubMed
  53. 53.↵
    1. SongTao Q,
    2. Lei Y,
    3. Si G, et al
    . IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012;103:269–73 doi:10.1111/j.1349-7006.2011.02134.x pmid:22034964
    CrossRefPubMed
  54. 54.↵
    1. Buckner JC,
    2. Shaw EG,
    3. Pugh SL, et al
    . Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016;374:1344–55 doi:10.1056/NEJMoa1500925 pmid:27050206
    CrossRefPubMed
  55. 55.↵
    1. Kim H,
    2. Kim S,
    3. Lee HH, et al
    . In-vivo proton magnetic resonance spectroscopy of 2-hydroxyglutarate in isocitrate dehydrogenase-mutated gliomas: a technical review for neuroradiologists. Korean J Radiol 2016;17:620–32 doi:10.3348/kjr.2016.17.5.620 pmid:27587950
    CrossRefPubMed
  56. 56.↵
    1. Ross B,
    2. Gambhir S
    1. Shim H
    . Spectroscopic MRI for brain tumor imaging, molecular imaging. In: Ross B, Gambhir S, eds. Molecular Imaging. Elsevier; 2021:1077–90
  57. 57.↵
    1. Suh CH,
    2. Kim HS,
    3. Jung SC, et al
    . 2-Hydroxyglutarate MRS for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data. Neuro Oncol 2018;20:1573–83 doi:10.1093/neuonc/noy113 pmid:30020513
    CrossRefPubMed
  58. 58.↵
    1. Andronesi OC,
    2. Kim GS,
    3. Gerstner E, et al
    . Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012;4:116ra4 doi:10.1126/scitranslmed.3002693 pmid:22238332
    Abstract/FREE Full Text
  59. 59.↵
    1. Chaumeil MM,
    2. Larson PE,
    3. Yoshihara HA, et al
    . Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun 2013;4:2429 doi:10.1038/ncomms3429 pmid:24019001
    CrossRefPubMed
  60. 60.↵
    1. An Z,
    2. Tiwari V,
    3. Baxter J, et al
    . 3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo. Magn Reson Med 2019;81:795–802 doi:10.1002/mrm.27482 pmid:30277274
    CrossRefPubMed
  61. 61.↵
    1. Provencher SW
    . Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260–64 doi:10.1002/nbm.698 pmid:11410943
    CrossRefPubMedWeb of Science
  62. 62.↵
    1. Huang LE
    . Friend or foe-IDH1 mutations in glioma 10 years on. Carcinogenesis 2019;40:1299–1307 doi:10.1093/carcin/bgz134 pmid:31504231
    CrossRefPubMed
  63. 63.↵
    1. Wang HY,
    2. Tang K,
    3. Liang TY, et al
    . The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res 2016;35:86 doi:10.1186/s13046-016-0362-7 pmid:27245697
    CrossRefPubMed
  64. 64.↵
    1. Molenaar RJ,
    2. Maciejewski JP,
    3. Wilmink JW, et al
    . Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene 2018;37:1949–60 doi:10.1038/s41388-017-0077-z pmid:29367755
    CrossRefPubMed
  65. 65.↵
    1. Han S,
    2. Liu Y,
    3. Cai SJ, et al
    . IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer 2020;122:1580–89 doi:10.1038/s41416-020-0814-x pmid:32291392
    CrossRefPubMed
  66. 66.↵
    1. Louis DN,
    2. Perry A,
    3. Wesseling P, et al
    . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076
    CrossRefPubMed
  67. 67.↵
    1. Camelo-Piragua S,
    2. Jansen M,
    3. Ganguly A, et al
    . Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 2010;119:509–11 doi:10.1007/s00401-009-0632-y pmid:20044756
    CrossRefPubMedWeb of Science
  68. 68.↵
    1. Takano S,
    2. Tian W,
    3. Matsuda M, et al
    . Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 2011;28:115–23 doi:10.1007/s10014-011-0023-7 pmid:21344322
    CrossRefPubMedWeb of Science
  69. 69.↵
    1. Takano S,
    2. Kato Y,
    3. Yamamoto T, et al
    . Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 2012;108:361–73 doi:10.1007/s11060-012-0837-0 pmid:22396072
    CrossRefPubMed
  70. 70.↵
    1. Hangel G,
    2. Cadrien C,
    3. Lazen P, et al
    . High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI. Neuroimage Clin 2020;28:102433 doi:10.1016/j.nicl.2020.102433 pmid:32977210
    CrossRefPubMed
  71. 71.↵
    1. Venkataramani V,
    2. Tanev DI,
    3. Strahle C, et al
    . Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 2019;573:532–38 doi:10.1038/s41586-019-1564-x pmid:31534219
    CrossRefPubMed
  72. 72.↵
    1. Ye ZC,
    2. Sontheimer H
    . Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999;59:4383–91 pmid:10485487
    Abstract/FREE Full Text
  73. 73.↵
    1. Hangel G,
    2. Jain S,
    3. Springer E, et al
    . High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T. Neuroimage 2019;191:587–95 doi:10.1016/j.neuroimage.2019.02.023 pmid:30772399
    CrossRefPubMed
  74. 74.↵
    1. Nanga RP,
    2. DeBrosse C,
    3. Kumar D, et al
    . Reproducibility of 2D GluCEST in healthy human volunteers at 7 T. Magn Reson Med 2018;80:2033–39 doi:10.1002/mrm.27362 pmid:29802635
    CrossRefPubMed
  75. 75.↵
    1. Libby CJ,
    2. Tran AN,
    3. Scott SE, et al
    . The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells. Biochim Biophys Acta Rev Cancer 2018;1869:175–88 doi:10.1016/j.bbcan.2018.01.004 pmid:29378228
    CrossRefPubMed
  76. 76.↵
    1. Tardito S,
    2. Oudin A,
    3. Ahmed SU, et al
    . Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol 2015;17:1556–68 doi:10.1038/ncb3272 pmid:26595383
    CrossRefPubMed
  77. 77.↵
    1. Hingerl L,
    2. Strasser B,
    3. Moser P, et al
    . Clinical high-resolution 3D-MR spectroscopic imaging of the human brain at 7 T. Invest Radiol 2020;55:239–48 doi:10.1097/RLI.0000000000000626 pmid:31855587
    CrossRefPubMed
  78. 78.↵
    1. Altman BJ,
    2. Stine ZE,
    3. Dang CV
    . From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer 2016;16:619–34 doi:10.1038/nrc.2016.71 pmid:27492215
    CrossRefPubMed
  79. 79.↵
    1. Koch K,
    2. Hartmann R,
    3. Tsiampali J, et al
    . A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity. Cell Death Discov 2020;6:20 doi:1[0.1038/s41420-020-0258-3 pmid:32337072
    CrossRefPubMed
  80. 80.↵
    1. Wang JB,
    2. Erickson JW,
    3. Fuji R, et al
    . Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010;18:207–19 doi:10.1016/j.ccr.2010.08.009 pmid:20832749
    CrossRefPubMedWeb of Science
  81. 81.↵
    1. Ekici S,
    2. Risk BB,
    3. Neill SG, et al
    . Characterization of dysregulated glutamine metabolism in human glioma tissue with 1H NMR. Sci Rep 2020;10:20435 doi:10.1038/s41598-020-76982-7 pmid:33235296
    CrossRefPubMed
  82. 82.↵
    1. Obara-Michlewska M,
    2. Szeliga M
    . Targeting glutamine addiction in gliomas. Cancers (Basel) 2020;12:310 doi:10.3390/cancers12020310 pmid:32013066
    CrossRefPubMed
  83. 83.↵
    1. Song M,
    2. Kim SH,
    3. Im CY, et al
    . Recent development of small molecule glutaminase inhibitors. Curr Top Med Chem 2018;18:432–43 doi:10.2174/1568026618666180525100830 pmid:29793408
    CrossRefPubMed
  84. 84.↵
    1. Wang Z,
    2. Liu F,
    3. Fan N, et al
    . Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies. Front Oncol 2020;10:589508 doi:10.3389/fonc.2020.589508 pmid:33194749
    CrossRefPubMed
  85. 85.↵
    1. Shen YA,
    2. Chen CL,
    3. Huang YH, et al
    . Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment. Curr Opin Chem Biol 2021;62:64–81 doi:10.1016/j.cbpa.2021.01.006 pmid:33721588
    CrossRefPubMed
  86. 86.↵
    1. Choi C,
    2. Ganji SK,
    3. DeBerardinis RJ, et al
    . Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors. Magn Reson Med 2011;66:609–18 doi:10.1002/mrm.22857 pmid:21394775
    CrossRefPubMed
  87. 87.↵
    1. Kinoshita Y,
    2. Kajiwara H,
    3. Yokota A, et al
    . Proton magnetic resonance spectroscopy of astrocytic tumors: an in vitro study. Neurol Med Chir (Tokyo) 1993;33:350–59 doi:10.2176/nmc.33.350 pmid:7689180
    CrossRefPubMed
  88. 88.↵
    1. Righi V,
    2. Andronesi OC,
    3. Mintzopoulos D, et al
    . High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int J Oncol 2010;36:301–06 doi:10.3892/ijo_00000500 pmid:20043062
    CrossRefPubMedWeb of Science
  89. 89.↵
    1. Prisciandaro JJ,
    2. Schacht JP,
    3. Prescot AP, et al
    . Evidence for a unique association between fronto-cortical glycine levels and recent heavy drinking in treatment naive individuals with alcohol use disorder. Neurosci Lett 2019;706:207–10 doi:10.1016/j.neulet.2019.05.030 pmid:31108129
    CrossRefPubMed
  90. 90.↵
    1. Stence NV,
    2. Fenton LZ,
    3. Levek C, et al
    . Brain imaging in classic nonketotic hyperglycinemia: Quantitative analysis and relation to phenotype. J Inherit Metab Dis 2019;42:438–50 doi:10.1002/jimd.12072 pmid:30737808
    CrossRefPubMed
  91. 91.↵
    1. Tiwari V,
    2. Daoud EV,
    3. Hatanpaa KJ, et al
    . Glycine by MRS is an imaging biomarker of glioma aggressiveness. Neuro Oncol 2020;22:1018–29 doi:10.1093/neuonc/noaa034 pmid:32055850
    CrossRefPubMed
  92. 92.↵
    1. Seliger C,
    2. Schaertl J,
    3. Gerken M, et al
    . Use of statins or NSAIDs and survival of patients with high-grade glioma. PLoS One 2018;13:e0207858 doi:10.1371/journal.pone.0207858 pmid:30507932
    CrossRefPubMed
  93. 93.↵
    1. Avdievich NI,
    2. Pan JW,
    3. Baehring JM, et al
    . Short echo spectroscopic imaging of the human brain at 7T using transceiver arrays. Magn Reson Med 2009;62:17–25 doi:10.1002/mrm.21970 pmid:19365851
    CrossRefPubMed
  94. 94.↵
    1. Strasser B,
    2. Chmelik M,
    3. Robinson SD, et al
    . Coil combination of multichannel MRSI data at 7 T: MUSICAL. NMR Biomed 2013;26:1796–805 doi:10.1002/nbm.3019 pmid:24038331
    CrossRefPubMed
  95. 95.↵
    1. Feldman RE,
    2. Balchandani P
    . A semiadiabatic spectral-spatial spectroscopic imaging (SASSI) sequence for improved high-field MR spectroscopic imaging. Magn Reson Med 2016;76:1071–82 doi:10.1002/mrm.26025 pmid:26519948
    CrossRefPubMed
  96. 96.↵
    1. Balchandani P,
    2. Pauly J,
    3. Spielman D
    . Designing adiabatic radio frequency pulses using the Shinnar-Le Roux algorithm. Magn Reson Med 2010;64:843–51 doi:10.1002/mrm.22473 pmid:20806378
    CrossRefPubMed
  97. 97.↵
    1. Li N,
    2. Li S,
    3. Shen J
    . High field in vivo 13C magnetic resonance spectroscopy of brain by random radiofrequency heteronuclear decoupling and data undersampling. Front Phys, 2017;5:26 doi:10.3389/fphy.2017.00026 pmid:29177139
    CrossRefPubMed
  98. 98.↵
    1. Wang Z,
    2. Lin JC,
    3. Mao W, et al
    . SAR and temperature: simulations and comparison to regulatory limits for MRI. J Magn Reson Imaging 2007;26:437–41 doi:10.1002/jmri.20977 pmid:17654736
    CrossRefPubMed
  99. 99.↵
    1. Ogg RJ,
    2. Kingsley PB,
    3. Taylor JS
    . WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMRS. J Magn Reson B 1994;104:1–10 doi:10.1006/jmrb.1994.1048 pmid:8025810
    CrossRefPubMedWeb of Science
  100. 100.↵
    1. Tkáč I,
    2. Gruetter R
    . Methodology of H NMR spectroscopy of the human brain at very high magnetic fields. Appl Magn Reson 2005;29:139–57 doi:10.1007/BF03166960 pmid:20179773
    CrossRefPubMed
  101. 101.↵
    1. Stockmann J,
    2. Witzel T,
    3. Arango N
    , et al. (2017) An integrated 32ch RF-shim array coil for improved B0 shimming of the brain at 7 Tesla. A. A. Martinos Center for Biomedical Imaging, Charlestown, MA, United States. International Society for Magnetic Resonance in Medicine (ISMRM).
  102. 102.↵
    1. Verma G,
    2. Chawla S,
    3. Nagarajan R, et al
    . Non-uniformly weighted sampling for faster localized two-dimensional correlated spectroscopy of the brain in vivo. J Magn Reson 2017;277:104–12 doi:10.1016/j.jmr.2017.02.012 pmid:28262561
    CrossRefPubMed
  103. 103.↵
    1. Fu Y,
    2. Ijare O,
    3. Thomas G, et al
    . Implementation of wavelet encoding spectroscopic imaging technique on a 3 Tesla whole body MR scanner: in vitro results. In: Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Minneapolis, MN, USA. September 3–6, 2009:2688–91
  104. 104.↵
    1. Geethanath S,
    2. Baek HM,
    3. Ganji SK, et al
    . Compressive sensing could accelerate 1H MR metabolic imaging in the clinic. Radiology 2012;262:985–94 doi:10.1148/radiol.11111098 pmid:22357898
    CrossRefPubMed
  105. 105.↵
    1. Cao P,
    2. Shin PJ,
    3. Park I, et al
    . Accelerated high-bandwidth MR spectroscopic imaging using compressed sensing. Magn Reson Med 2016;76:369–79 doi:10.1002/mrm.26272 pmid:27228088
    CrossRefPubMed
  106. 106.↵
    1. Klauser A,
    2. Courvoisier S,
    3. Kasten J, et al
    . Fast high-resolution brain metabolite mapping on a clinical 3T MRI by accelerated 1 H-FID-MRSI and low-rank constrained reconstruction. Magn Reson Med 2019;81:2841–57 doi:10.1002/mrm.27623 pmid:30565314
    CrossRefPubMed
  107. 107.↵
    1. Bogner W,
    2. Otazo R,
    3. Henning A
    . Accelerated MR spectroscopic imaging-a review of current and emerging techniques. NMR Biomed 2021;34:e4314 doi:10.1002/nbm.4314 pmid:32399974
    CrossRefPubMed
  108. 108.↵
    1. Klauser A,
    2. Strasser B,
    3. Thapa B, et al
    . Achieving high-resolution whole-brain slab 1H-MRSI with compressed-sensing and low-rank reconstruction at 7 Tesla. J Magn Reson 2021;331:107048 doi:10.1016/j.jmr.2021.107048 pmid:34438355
    CrossRefPubMed
  109. 109.↵
    1. Verburg N,
    2. Koopman T,
    3. Yaqub MM, et al
    . Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro Oncol 2020;22:412–22 doi:10.1093/neuonc/noz180 pmid:31550353
    CrossRefPubMed
  110. 110.↵
    1. Verburg N,
    2. Hoefnagels FWA,
    3. Barkhof F, et al
    . Diagnostic accuracy of neuroimaging to delineate diffuse gliomas within the brain: a meta-analysis. AJNR Am J Neuroradiol 2017;38:1884–91 doi:10.3174/ajnr.A5368 pmid:28882867
    Abstract/FREE Full Text
  111. 111.↵
    1. Croteau D,
    2. Scarpace L,
    3. Hearshen D, et al
    . Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 2001;49:823–29 pmid:11564242
    CrossRefPubMedWeb of Science
  112. 112.↵
    1. van der Kolk AG,
    2. Hendrikse J,
    3. Zwanenburg JJM, et al
    . Clinical applications of 7 T MRI in the brain. Eur J Radiol 2013;82:708–18 doi:10.1016/j.ejrad.2011.07.007 pmid:21937178
    CrossRefPubMed
  113. 113.↵
    1. Cordova JS,
    2. Shu HK,
    3. Liang Z, et al
    . Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro Oncol 2016;18:1180–89 doi:10.1093/neuonc/now036 pmid:26984746
    CrossRefPubMed
  114. 114.↵
    1. Hangel G,
    2. Strasser B,
    3. Považan M, et al
    . Ultra-high resolution brain metabolite mapping at 7 T by short-TR Hadamard-encoded FID-MRSI. Neuroimage 2018;168:199–210 doi:10.1016/j.neuroimage.2016.10.043 pmid:27825954
    CrossRefPubMed
  115. 115.↵
    1. Moenninghoff C,
    2. Kraff O,
    3. Schlamann M, et al
    . Assessing a dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease) with 7T MR imaging. Korean J Radiol 2010;11:244–48 doi:10.3348/kjr.2010.11.2.244 pmid:20191074
    CrossRefPubMed
  116. 116.↵
    1. Mönninghoff C,
    2. Maderwald S,
    3. Theysohn J, et al
    . Imaging of brain metastases of bronchial carcinomas with 7 T MRI: initial results. Rofo 2010;182:764–72 doi:10.1055/s-0029-1245440 pmid:20544578
    CrossRefPubMed
  117. 117.↵
    1. Lupo JM,
    2. Banerjee S,
    3. Hammond KE, et al
    . GRAPPA-based susceptibility-weighted imaging of normal volunteers and patients with brain tumor at 7 T. Magn Reson Imaging 2009;27:480–88 doi:10.1016/j.mri.2008.08.003 pmid:18823730
    CrossRefPubMedWeb of Science
  118. 118.↵
    1. Tsien C,
    2. Galbán CJ,
    3. Chenevert TL, et al
    . Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 2010;28:2293–99 doi:10.1200/JCO.2009.25.3971 pmid:20368564
    Abstract/FREE Full Text
  119. 119.↵
    1. Leao DJ,
    2. Craig PG,
    3. Godoy LF, et al
    . Response Assessment in Neuro-Oncology criteria for gliomas: practical approach using conventional and advanced techniques. AJNR Am J Neuroradiol 2020;41:10–20 doi:10.3174/ajnr.A6358 pmid:31857322
    Abstract/FREE Full Text
  120. 120.↵
    1. Chukwueke UN,
    2. Wen PY
    . Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol 2019;8:Cns28 doi:10.2217/cns-2018-0007 pmid:30806082
    CrossRefPubMed
  121. 121.↵
    1. Brandsma D,
    2. Stalpers L,
    3. Taal W, et al
    . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453–61 doi:10.1016/S1470-2045(08)70125-6 pmid:18452856
    CrossRefPubMedWeb of Science
  122. 122.↵
    1. Hygino da Cruz LC,
    2. Rodriguez I,
    3. Domingues RC Jr., et al
    . Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011;32:1978–85 doi:10.3174/ajnr.A2397 pmid:21393407
    Abstract/FREE Full Text
  123. 123.↵
    1. Chen X,
    2. Wei X,
    3. Zhang Z, et al
    . Differentiation of true-progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide by GLCM texture analysis of conventional MRI. Clin Imaging 2015;39:775–80 doi:10.1016/j.clinimag.2015.04.003 pmid:25956436
    CrossRefPubMed
  124. 124.↵
    1. Nasseri M,
    2. Gahramanov S,
    3. Netto JP, et al
    . Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol 2014;16:1146–54 doi:10.1093/neuonc/not328 pmid:24523362
    CrossRefPubMed
  125. 125.↵
    1. Zikou A,
    2. Sioka C,
    3. Alexiou GA, et al
    . Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol Imaging 2018;2018:6828396 doi:10.1155/2018/6828396 pmid:30627060
    CrossRefPubMed
  126. 126.↵
    1. Ma B,
    2. Blakeley JO,
    3. Hong X, et al
    . Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging 2016;44:456–62 doi:10.1002/jmri.25159 pmid:26788865
    CrossRefPubMed
  127. 127.↵
    1. Thust SC,
    2. van den Bent MJ,
    3. Smits M
    . Pseudoprogression of brain tumors. J Magn Reson Imaging 2018;48:571–89 doi:10.1002/jmri.26171 pmid:29734497
    CrossRefPubMed
  128. 128.↵
    1. Brandes AA,
    2. Tosoni A,
    3. Spagnolli F, et al
    . Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008;10:361–67 doi:10.1215/15228517-2008-008 pmid:18401015
    CrossRefPubMed
  129. 129.↵
    1. Gahramanov S,
    2. Muldoon LL,
    3. Varallyay CG, et al
    . Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 2013;266:842–52 doi:10.1148/radiol.12111472 pmid:23204544
    CrossRefPubMedWeb of Science
  130. 130.↵
    1. Cha J,
    2. Kim ST,
    3. Kim H-J, et al
    . Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. AJNR Am J Neuroradiol 2014;35:1309–17 doi:10.3174/ajnr.A3876 pmid:24676005
    Abstract/FREE Full Text
  131. 131.↵
    1. Choi YJ,
    2. Kim HS,
    3. Jahng G-H, et al
    . Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging. Acta Radiol 2013;54:448–54 doi:10.1177/0284185112474916 pmid:23592805
    CrossRefPubMed
  132. 132.↵
    1. Shim H,
    2. Holder CA,
    3. Olson JJ
    . Magnetic resonance spectroscopic imaging in the era of pseudoprogression and pseudoresponse in glioblastoma patient management. CNS Oncol 2013;2:393–96 doi:10.2217/cns.13.39 pmid:25054660
    CrossRefPubMed
  133. 133.↵
    1. Abbasi AW,
    2. Westerlaan HE,
    3. Holtman GA, et al
    . Incidence of tumour progression and pseudoprogression in high-grade gliomas: a systematic review and meta-analysis. Clin Neuroradiol 2018;28:401–11 doi:10.1007/s00062-017-0584-x pmid:28466127
    CrossRefPubMed
  134. 134.↵
    1. Andronesi OC,
    2. Esmaeili M,
    3. Borra RJ, et al
    . Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol 2017;1:120 doi:10.1038/s41698-017-0020-3 pmid:29202103
    CrossRefPubMed
  135. 135.↵
    1. Li M,
    2. Ren X,
    3. Dong G, et al
    . Distinguishing pseudoprogression from true early progression in isocitrate dehydrogenase wild-type glioblastoma by interrogating clinical, radiological, and molecular features. Front Oncol 2021;11:627325 doi:10.3389/fonc.2021.62732]5 pmid:33515701
    CrossRefPubMed
  136. 136.↵
    1. Le Fevre C,
    2. Constans JM,
    3. Chambrelant I, et al
    . Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review, Part 2: radiological features and metric markers. Crit Rev Oncol Hematol 2021;159:103230 doi:10.1016/j.critrevonc.2021.103230 pmid:33515701
    CrossRefPubMed
  137. 137.↵
    1. Kamada K,
    2. Houkin K,
    3. Abe H, et al
    . Differentiation of cerebral radiation necrosis from tumor recurrence by proton magnetic resonance spectroscopy. Neurol Med Chir (Tokyo) 1997;37:250–56 doi:10.2176/nmc.37.250 pmid:9095625
    CrossRefPubMed
  138. 138.↵
    1. Fink J,
    2. Born D,
    3. Chamberlain MC
    . Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol 2011;12:240–52 doi:10.1007/s11864-011-0157-1 pmid:21594589
    CrossRefPubMed
  139. 139.↵
    1. Seeger A,
    2. Braun C,
    3. Skardelly M, et al
    . Comparison of three different MR perfusion techniques and MRS for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease. Acad Radiol 2013;20:1557–65 doi:10.1016/j.acra.2013.09.003 pmid:24200483
    CrossRefPubMed
  140. 140.↵
    1. Elias AE,
    2. Carlos RC,
    3. Smith EA, et al
    . MRS using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol 2011;18:1101–08 doi:10.1016/j.acra.2011.05.006 pmid:21820634
    CrossRefPubMed
  141. 141.↵
    1. Smith EA,
    2. Carlos RC,
    3. Junck LR, et al
    . Developing a clinical decision model: MRS to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009;192:W45–52 doi:10.2214/AJR.07.3934 pmid:19155380
    CrossRefPubMedWeb of Science
  142. 142.↵
    1. Weybright P,
    2. Sundgren PC,
    3. Maly P, et al
    . Differentiation between brain tumor recurrence and radiation injury using MRS. AJR Am J Roentgenol 2005;185:1471–76 doi:10.2214/AJR.04.0933 pmid:16304000
    CrossRefPubMedWeb of Science
  143. 143.↵
    1. Zeng QS,
    2. Li CF,
    3. Zhang K, et al
    . Multivoxel 3D proton MRS in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007;84:63–69 doi:10.1007/s11060-007-9341-3 pmid:17619225
    CrossRefPubMed
  144. 144.↵
    1. Knudsen-Baas KM,
    2. Moen G,
    3. Fluge Ø, et al
    . Pseudoprogression in high-grade glioma. Acta Neurol Scand 2013;127:31–37 doi:10.1111/ane.12047 pmid:23190289
    CrossRefPubMed
  145. 145.↵
    1. Verma G,
    2. Chawla S,
    3. Mohan S, et al
    . Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. NMR Biomed 2019;32:e4042 doi:10.1002/nbm.4042 pmid:30556932
    CrossRefPubMed
  146. 146.↵
    1. Kong DS,
    2. Kim ST,
    3. Kim EH, et al
    . Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382–87 doi:10.3174/ajnr.A2286 pmid:21252041
    Abstract/FREE Full Text
  147. 147.↵
    1. Pohmann R,
    2. Speck O,
    3. Scheffler K
    . Signal-to-noise ratio and MR tissue parameters in human brain imaging at 3, 7, and 9.4 Tesla using current receive coil arrays. Magn Reson Med 2016;75:801–09 doi:10.1002/mrm.25677 pmid:25820458
    CrossRefPubMed
  148. 148.↵
    1. Wiggins GC,
    2. Potthast A,
    3. Triantafyllou C, et al
    . Eight-channel phased array coil and detunable TEM volume coil for 7 T brain imaging. Magn Reson Med 2005;54:235–40 doi:10.1002/mrm.20547 pmid:15968650
    CrossRefPubMedWeb of Science
  149. 149.↵
    1. Oz G,
    2. Deelchand DK,
    3. Wijen JP, et al
    . Advanced single voxel 1H magnetic resonance spectroscopy techniques in humans: experts’ consensus recommendations. NMR Biomed 2020;e4236 doi:10.1002/nbm.4236 pmid:31922301
    CrossRefPubMed
  150. 150.↵
    1. Tkac I,
    2. Oz G,
    3. Gruetter R
    . Comparison of metabolite quantification in the human brain at 4 and 7 Tesla. In: Proceedings of the Scientific Meeting and Exhibition of the International Society for Magnetic Imaging in Medicine, Miami Beach, Florida. May 7–13, 2005:2458
  151. 151.↵
    1. Su C,
    2. Liu C,
    3. Zhao L, et al
    . Amide proton transfer imaging allows detection of glioma grades and tumor proliferation: comparison with Ki-67 expression and proton MR spectroscopy imaging. AJNR Am J Neuroradiol 2017;38:1702–19 doi:10.3174/ajnr.A5301 pmid:28729292
    Abstract/FREE Full Text
  152. 152.↵
    1. Kim JH,
    2. Chang KH,
    3. Na DG, et al
    . 3T 1H-MRS in grading of cerebral gliomas: comparison of short and intermediate echo time sequences. AJNR Am J Neuroradiol 2006;27:1412–18 pmid:16908549
    PubMedWeb of Science
  153. 153.↵
    1. Fudaba H,
    2. Shimomura T,
    3. Abe T, et al
    . Comparison of multiple parameters obtained on 3T pulsed arterial spin-labeling, diffusion tensor imaging, and MRS and the Ki-67 labeling index in evaluating glioma grading. AJNR Am J Neuroradiol 2014;35:2091–98 doi:10.3174/ajnr.A4018 pmid:24994829
    Abstract/FREE Full Text
  154. 154.↵
    1. Vamvakas A,
    2. Williams SC,
    3. Theodorou K, et al
    . Imaging biomarker analysis of advanced multiparametric MRI for glioma grading. Phys Med 2019;60:188–98 doi:10.1016/j.ejmp.2019.03.014 pmid:30910431
    CrossRefPubMed
  155. 155.↵
    1. Senft C,
    2. Hattingen E,
    3. Pilatus U, et al
    . Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery 2009;65:908–13; discussion 913 doi:10.1227/01.NEU.0000356982.82378.BA pmid:19834403
    CrossRefPubMedWeb of Science
  156. 156.↵
    1. Sakata A,
    2. Fushimi Y,
    3. Okada T, et al
    . Diagnostic performance between contrast enhancement, proton MRS, and amide proton transfer imaging in patients with brain tumors. J Magn Reson Imaging 2017;46:732–39 doi:10.1002/jmri.25597 pmid:28252822
    CrossRefPubMed
  157. 157.↵
    1. Bradac O,
    2. Vrana J,
    3. Jiru F, et al
    . Recognition of anaplastic foci within low-grade gliomas using MRS. Br J Neurosurg 2014;28:631–36 doi:10.3109/02688697.2013.872229 pmid:24377726
    CrossRefPubMed
  158. 158.↵
    1. Chung C,
    2. Metser U,
    3. Menard C
    . Advances in magnetic resonance imaging and positron emission tomography imaging for grading and molecular characterization of glioma. Semin Radiat Oncol 2015;25:164–71 doi:10.1016/j.semradonc.2015.02.002 pmid:26050586
    CrossRefPubMed
  159. 159.↵
    1. Delikatny EJ,
    2. Chawla S,
    3. Leung D-J, et al
    . MR-visible lipids and the tumor microenvironment. NMR Biomed 2011;24:592–611 doi:10.1002/nbm.1661 pmid:21538631
    CrossRefPubMedWeb of Science
  160. 160.↵
    1. Feng DX,
    2. McCauley JP,
    3. Morgan–Curtis FK, et al
    . Evaluation of 39 medical implants at 7.0 T. Br J Radiol 2015;88:20150633 doi:10.1259/bjr.20150633 pmid:26481696
    CrossRefPubMed
  161. 161.↵
    1. Kraff O,
    2. Wrede KH,
    3. Schoemberg T, et al
    . MR safety assessment of potential RF heating from cranial fixation plates at 7 T. Med Phys 2013;40:042302 doi:10.1118/1.4795347 pmid:23556915
    CrossRefPubMed
  162. 162.↵
    1. Chen B,
    2. Schoemberg T,
    3. Kraff O, et al
    . Cranial fixation plates in cerebral magnetic resonance imaging: a 3 and 7 Tesla in vivo image quality study. MAGMA 2016;29:389–98 doi:10.1007/s10334-016-0548-1 pmid:27026243
    CrossRefPubMed
  163. 163.↵
    1. Kraff O,
    2. Quick HH
    . 7T: Physics, safety, and potential clinical applications. J Magn Reson Imaging 2017;46:1573–89 doi:10.1002/jmri.25723 pmid:28370675
    CrossRefPubMed
  164. 164.↵
    1. Okada T,
    2. Akasaka T,
    3. Thuy DH, et al
    . Safety for human MR scanners at 7T. Magn Reson Med Sci 2021 Aug 6 [Epub ahead of print] doi:10.2463/mrms.rev.2021-0063 pmid:34373430
    CrossRefPubMed
  165. 165.↵
    1. Fagan AJ,
    2. Bitz AK,
    3. Björkman-Burtscher IM, et al
    ; ISMRM Safety Committee. 7T MR safety. J Magn Reson Imaging 2021;53:333–46 doi:10.1002/jmri.27319 pmid:32830900
    CrossRefPubMed
  166. 166.↵
    1. Moser E,
    2. Stahlberg F,
    3. Ladd ME, et al
    . 7-T MR: from research to clinical applications? NMR Biomed 2012;25:695–716 doi:10.1002/nbm.1794 pmid:22102481
    CrossRefPubMed
  167. 167.↵
    1. Mikkelsen M,
    2. Rimbault DL,
    3. Barker PB, et al
    . Big GABA II: water-referenced edited MRS at 25 research sites. Neuroimage 2019;191:537–48 doi:10.1016/j.neuroimage.2019.02.059 pmid:30840905
    CrossRefPubMed
  168. 168.↵
    1. Near J,
    2. Harris AD,
    3. Juchem C, et al
    . Preprocessing, analysis and quantification in single-voxel magnetic resonance spectroscopy: experts’ consensus recommendations. NMR Biomed 2021;34:e4257 doi:10.1002/nbm.4257]
    CrossRefPubMed
  169. 169.↵
    1. Branzoli F,
    2. Di Stefano AL,
    3. Capelle L, et al
    . Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Neuro Oncol 2018;20:907–16 doi:10.1093/neuonc/nox214 pmid:29126125
    CrossRefPubMed
  170. 170.↵
    1. Vareth M,
    2. Lupo J,
    3. Larson P, et al
    . A comparison of coil combination strategies in 3D multi-channel MRSI reconstruction for patients with brain tumors. NMR Biomed 2018;31:e3929 doi:10.1002/nbm.3929 pmid:30168205
    CrossRefPubMed
  171. 171.↵
    1. Neal A,
    2. Moffat BA,
    3. Stein JM, et al
    . Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging. Neuroimage Clin 2019;22:101694 doi:10.1016/j.nicl.2019.101694 pmid:30822716
    CrossRefPubMed
  172. 172.↵
    1. Kudo H,
    2. Mio T,
    3. Kokunai T, et al
    . Quantitative analysis of glutathione in human brain tumors. J Neurosurg 1990;72:610–15 doi:10.3171/jns.1990.72.4.0610 pmid:1690792
    CrossRefPubMedWeb of Science
  173. 173.↵
    1. Rocha CR,
    2. Garcia CC,
    3. Vieira DB, et al
    . Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis 2014;5:e1505 doi:10.1038/cddis.2014.465 pmid:25356874
    CrossRefPubMed
  174. 174.↵
    1. Prisciandaro JJ,
    2. Mikkelsen M,
    3. Saleh MG, et al
    . An evaluation of the reproducibility of (1)H-MRS GABA and GSH levels acquired in healthy volunteers with J-difference editing sequences at varying echo times. Magn Reson Imaging 2020;65:109–13 doi:10.1016/j.mri.2019.10.004 pmid:31707293
    CrossRefPubMed
  175. 175.↵
    1. Bottino F,
    2. Lucignani M,
    3. Napolitano A, et al
    . In vivo brain GSH: MRS methods and clinical applications. Antioxidants (Basel) 2021;10:1407 doi:10.3390/antiox10091407 pmid:34573039
    CrossRefPubMed
  176. 176.↵
    1. Branco M,
    2. Linhares P,
    3. Carvalho B, et al
    . Serum lactate levels are associated with glioma malignancy grade. Clin Neurol Neurosurg 2019;186:105546 doi:10.1016/j.clineuro.2019.105546 pmid:31605893
    CrossRefPubMed
  177. 177.↵
    1. Reuss AM,
    2. Gross D,
    3. Buchfelder M, et al
    . The acidic brain-glycolytic switch in the microenvironment of malignant glioma. Int J Mol Sci 2021;22:5518 doi:10.3390/ijms22115518 pmid:34073734
    CrossRefPubMed
  178. 178.↵
    1. Daniele S,
    2. Giacomelli C,
    3. Zappelli E, et al
    . Lactate dehydrogenase: A inhibition induces human glioblastoma multiforme stem cell differentiation and death. Sci Rep 2015;5:15556 doi:10.1038/srep15556 pmid:26494310
    CrossRefPubMed
  179. 179.↵
    1. de la Cruz-López KG,
    2. Castro-Muñoz LJ,
    3. Reyes-Hernández DO, et al
    . Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol 2019;9:1143 doi:10.3389/fonc.2019.01143 pmid:31737570
    CrossRefPubMed
  180. 180.↵
    1. Bulik M,
    2. Jancalek R,
    3. Vanicek J, et al
    . Potential of MRS for assessment of glioma grading. Clin Neurol Neurosurg 2013;115:146–53 doi:10.1016/j.clineuro.2012.11.002 pmid:23237636
    CrossRefPubMed
  181. 181.↵
    1. Hérigault G,
    2. Zoula S.,
    3. Rémy C, et al
    . Multi-spin-echo J-resolved spectroscopic imaging without water suppression: application to a rat glioma at 7 T. MAGMA2004;17:140–48 doi:10.1007/s10334-004-0060-x pmid:15517469
    CrossRefPubMed
  182. 182.↵
    1. Gonen OM,
    2. Moffat BA,
    3. Kwan P, et al
    . Reproducibility of glutamate, glutathione, and GABA measurements in vivo by single-voxel STEAM magnetic resonance spectroscopy at 7-Tesla in healthy individuals. Front Neurosci 2020;14:566643 doi:10.3389/fnins.2020.566643 pmid:33041761
    CrossRefPubMed
Back to top

In this issue

Advertisement
Print
Download PDF
Email Article
Cite this article
0 Responses
Respond to this article
Bookmark this article
7T MRS in High-Grade Gliomas
L. McCarthy, G. Verma, G. Hangel, A. Neal, B.A. Moffat, J.P. Stockmann, O.C. Andronesi, P. Balchandani, C.G. Hadjipanayis
American Journal of Neuroradiology Oct 2022, 43 (10) 1378-1395; DOI: 10.3174/ajnr.A7502
del.icio.us logo Twitter logo Facebook logo Mendeley logo
Purchase

Jump to section

Advertisement